ESC Premium Access

Efficacy and safety of early switch to oral anticoagulation in acute intermediate-risk pulmonary embolism

Congress Presentation

About the speaker

Doctor Erik Klok

Leiden University Medical Centre, Leiden (Netherlands (The))
3 presentations
0 follower

73 more presentations in this session

The novel noninvasive method for prediction of long-term specific therapy efficacy in patients with IPAH and inoperable CTEPH

Speaker: Mrs I. Lyapina (Kemerovo, RU)

Thumbnail

Early and long term prognostic accuracy of 4 acute pulmonary embolism mortality risk scores

Speaker: Doctor L. Oliveira (Ponta Delgada, PT)

Thumbnail

Novel genetic and molecular pathways in pulmonary arterial hypertension associated with connective tissue disease

Speaker: Doctor I. Hernandez Gonzalez (Valladolid, ES)

Thumbnail

Role of echocardiography to avoid misclassification of pulmonary hypertension associated with left heart disease as precapillary pulmonary hypertension.

Speaker: Assistant Professor J. Grignola Rial (Montevideo, UY)

Thumbnail

Survival of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension listed for lung transplantation

Speaker: Doctor I. Magnani (Bologna, IT)

Thumbnail

Access the full session

Pulmonary circulation, pulmonary embolism, right heart failure e-posters

Speakers: Doctor E. Klok, Mrs I. Lyapina, Doctor L. Oliveira, Doctor I. Hernandez Gonzalez, Assistant Professor J. Grignola Rial...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Renal decline in patients with atrial fibrillation treated with rivaroxaban or warfarin: a population-based cohort study in the United Kingdom

27 August 2021

ESC Premium Access

Pregnancy and pulmonary hypertension.

27 August 2021

ESC Premium Access

Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials

27 August 2021

ESC 365 is supported by

logo Novo Nordisk